Hepatitis C is a viral disease that leads to swelling (inflammation) of the liver.
Other types of viral hepatitis include:
Sustained virologic response - hepatitis C; SVR - hepatitis C
Hepatitis C infection is caused by the hepatitis C virus (HCV).
You can catch hepatitis C if the blood of someone who has hepatitis C enters your body. Exposure may occur:
People at risk of hepatitis C are those who:
Most people who are recently infected with hepatitis C do not have symptoms in most cases. Some people have yellowing of the skin (jaundice) that goes away. Chronic infection often causes no symptoms. But tiredness, skin disorders and other problems can occur.
Persons who have long-term (chronic) infection often have no symptoms until their liver becomes scarred (cirrhosis). Most people with this condition are ill and have many health problems.
The following symptoms may occur with hepatitis C infection:
Exams and Tests
Blood tests are done to check for hepatitis C:
Everyone born from 1945 to 1965 (the baby boomer generation) should get a one-time test for hepatitis C.
Genetic testing is done to check for the type of hepatitis C (genotype). There are six types of the virus (genotypes 1 through 6). Test results can help your health care provider choose treatment that is best for you.
The following tests are done to identify and monitor liver damage from hepatitis C:
You should talk to your provider about your treatment options and when treatment should begin.
Medicines used to treat hepatitis C are called antiviral drugs because they fight the HCV. Newer antiviral drugs:
The choice of which drug depends on the genotype of the virus you have.
A liver transplant may be recommended for people who develop cirrhosis and liver cancer. Your provider can tell you more about liver transplant.
If you have hepatitis C:
Joining a support group can help ease the stress of having hepatitis C. Ask your provider about liver disease resources and support groups in your area.
Most people (75% to 85%) who are infected with the virus develop chronic hepatitis C. This condition poses a risk for cirrhosis, liver cancer, or both. The outlook for hepatitis C depends in part on the genotype.
A good response to treatment occurs when the virus can no longer be detected in the blood 12 weeks or more after treatment. This is called "sustained virologic response" (SVR). Up to 90% of those treated for some genotypes have this type of response.
Some people do not respond to initial treatment. They may need to be re-treated with a different drug regimen.
Also, some people can become re-infected or infected with a different genotype strain.
When to Contact a Medical Professional
Call your provider if:
Steps that can be taken to help prevent the spread of hepatitis C from one person to another include:
If you or your partner is infected with hepatitis C and you have been in a stable and monogamous (no other partners) relationship, the risk of giving the virus to, or getting the virus from, the other person is low.
HCV cannot be spread by casual contact, such as holding hands, kissing, coughing or sneezing, breastfeeding, sharing eating utensils or drinking glasses.
Currently there is no vaccine for hepatitis C.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898. PMID: 24725239 www.ncbi.nlm.nih.gov/pubmed/24725239.
Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374. PMID: 19330875 www.ncbi.nlm.nih.gov/pubmed/19330875.
Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631-640. PMID: 25117132 www.ncbi.nlm.nih.gov/pubmed/25117132.
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-1765. PMID: 25078309 www.ncbi.nlm.nih.gov/pubmed/25078309.
Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults. U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;159(5):349-357. PMID: 23798026 www.ncbi.nlm.nih.gov/pubmed/23798026.
Ray SC, Thomas DL. Hepatitis C. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 156.
Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-38. PMID: 21696309 www.ncbi.nlm.nih.gov/pubmed/21696309.
Wedemeyer H. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 80.
Review Date: 1/28/2016
Reviewed By: Subodh K. Lal, MD, gastroenterologist at Gastrointestinal Specialists of Georgia, Austell, GA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.